Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q1 2026 (March 31)7holders −1
0new positions
1sold out
$16.14avg. 13F price*
At the end of Q1 2026, 7 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, down 1 from Q4 2025. 0 opened new positions and 1 sold out. The largest holders were Hantz Financial Services, Inc. ($3.3M), Lanark Financial, Inc. ($710K) and Rhumbline Advisers ($354K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $4K |
All 13F filers, Q4 2025 → Q1 2026: 4,160 shares bought and 25,131 shares sold, net −20,971 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Hantz Financial Services, Inc. | 0.05% | Reduce -7.7% | 200,698 | $3.3M |
| Lanark Financial, Inc. | 0.05% | Reduce -12.7% | 44,856 | $710K |
| Rhumbline Advisers | 0.00% | Reduce -6.8% | 21,804 | $354K |
| GAMMA Investing LLC | 0.01% | Add +17.8% | 12,771 | $207K |
| Salomon & Ludwin, LLC | 0.00% | Add +231.3% | 2,432 | $40K |
| Wellington-Altus USA Inc. | 0.02% | Add +35.7% | 2,017 | $27K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 56 | $908 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.